A recent study reported that indacaterol/glycopyrrolate (Utibron Neohaler) inhalation powder improved lung function in people with moderate- to-severe chronic obstructive pulmonary disease (COPD). Utibron Neohaler is a combination of a long-acting beta agonist (indacaterol) and an anticholinergic drug (glycopyrrolate). This combination works together to increase airflow by relaxing the muscles around the lungs’ airways. Utibron Neohaler was studied in adults with COPD. When compared to a placebo, individuals who were given Utibron Neoholer for 12 weeks had a continual improvement in lung function, fewer shortness of breath, and a better health-related quality of life. Additionally, individuals taking Utibron Neohaler experienced fewer nighttime COPD symptoms and less nighttime awakenings.
COPD is a lung disorder that blocks airflow from the lungs. It may be caused by cigarette smoke or other gases. Symptoms of COPD may include shortness of breath, wheezing, and tightness in the chest area.